AI Terminal
Active Biotech
Declaration of Voting Results & Voting Rights Announcements • Dec 29, 2023
3133_rns_2023-12-29_dac618e4-0608-45bc-ab0e-8bbf4502680c.pdf
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
Number of shares and votes in Active Biotech
The number of shares and votes in Active Biotech AB (publ) has changed as a result of the recently completed rights issue.
Today, the last trading day of the month, there are in total 361,739,047 shares and votes in Active Biotech.
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, [email protected] Hans Kolam, CFO, +46 46 19 20 44, [email protected]
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in clinical development for treatment of non-infectious uveitis and a clinical phase I study with a topical ophthalmic formulation has been concluded. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www. activebiotech.com for more information.
This information is information that Active Biotech is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-12-29 08:30 CET.